Pregnancy outcomes from more than 1,800 in vitro fertilization cycles with the use of 24-chromosome single-nucleotide polymorphism-based preimplantation genetic testing for aneuploidy

Pregnancy outcomes from more than 1,800 in vitro fertilization cycles with the use of 24-chromosome single-nucleotide polymorphism-based preimplantation genetic testing for aneuploidy
复制标题

DOI:
10.1016/j.fertnstert.2018.03.026
复制
发表时间:
2018-07-01
影响因子:
6.7
通讯作者:
Demko, Zachary P.
Demko, Zachary P.
中科院分区:
医学2区
文献类型:
--
作者:
Simon, Alexander L.;Kiehl, Michelle;Demko, Zachary P.

文献摘要

被引文献

相似文献

目的:测量 24 染色体单染色体体外受精 (IVF) 的结果。基于核苷酸多态性 (SNP) 的非整倍体 (PGT-A) 和整倍体胚胎移植的植入前基因检测。设计:回顾性。设置:生育诊所和实验室。患者:接受 IVF 治疗的 20-46 岁女性。干预措施:第 5/6 天胚胎活检的基于 24 条染色体 SNP 的 PGT-A。主要结果衡量标准:母亲年龄分层的着床率、临床妊娠率和每次胚胎移植的活产率;流产率;结果:使用基于 SNP 的 PGT-A 在 1,621 个非供体冷冻周期中观察到,植入率为 69.9%,每次移植的临床妊娠率为 70.6%,每次移植的活产率为 64.5%。此外,在每个周期进行移植测量时,基于 SNP 的 PGT-A 结果在所有年龄的母亲中保持相对稳定;当每个周期开始时进行测量时,它们随着母亲年龄的增加而减少。女性流产率约为 5%
Objective: To measure in vitro fertilization (IVF) outcomes following 24-chromosome single. nucleotide-polymorphism (SNP)-based preimplantation genetic testing for aneuploidy (PGT-A) and euploid embryo transfer.Design: Retrospective.Setting: Fertility clinics and laboratory.Patient(s): Women 20-46 years of age undergoing IVF treatment.Intervention(s): Twenty-four-chromosome SNP-based PGT-A of day 5/6 embryo biopsies.Main Outcome Measure(s): Maternal age-stratified implantation, clinical pregnancy, and live birth rates per embryo transfer; miscarriage rates; and number of embryo transfers per patient needed to achieve a live birth.Result(s): An implantation rate of 69.9%, clinical pregnancy rate per transfer of 70.6%, and live birth rate per transfer of 64.5% were observed in 1,621 nondonor frozen cycles with the use of SNP-based PGT-A. In addition, SNP-based PGT-A outcomes, when measured per cycle with transfer, remained relatively constant across all maternal ages; when measured per cycle initiated, they decreased as maternal age increased. Miscarriage rates were similar to 5% in women